B
Bullisch
Bullisch · 25%PPBT
$2.79
Szenariopreis
$1.280
+0.031 (+2.40%)Zum Schluss
Loading chart…
- Hoch
- 1.330
- Eröffnung
- 1.150
- Volumengewichteter Durchschnittskurs
- 1.25
- Volumen
- 42.46K
- Marktkap.
- 11.43M
- Tief
- 1.150
- Umsatz
- 53.22K
- EV/EBITDA, TTM
- 0.00
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
KI-Analyse of Purple Biotech Ltd (PPBT)
HaltenCurrently, Purple Biotech Ltd is not a strong buy due to its significant financial losses and high volatility. The current price is $1.28, with a 52-week high of $8.90, indicating a potential for recovery but also a risk of further decline. The RSI is at 70.565, suggesting it may be overbought, and the forward P/E ratio is 0, indicating uncertainty in future earnings. The main risk is the projected EPS loss of -2.88 for the upcoming earnings report, which could further impact investor sentiment.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Purple Biotech Ltd (PPBT) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -7.75.
Alphio-AI-Kursszenarien für PPBT
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Event-Zeitleiste
News
8.509-02NewsfilterPurple Biotech Secures Patent Allowance for Tri-Specific Antibodies
- 8.506-11Newsfilter
Purple Biotech's IM1240 Study Advances with Promising Results
9.505-15seekingalphaPurple Biotech Reports Q1 2026 Financial Results
9.004-23moomooPURPLE BIOTECH LTD FORMS SCIENTIFIC ADVISORY BOARD FOR CAPTN-3 ANTIBODY PLATFORM
7.503-25moomooPurple Biotech Partners with Converge Bio to Enhance Development of Next-Generation Tri-Specific Antibody Platform Using AI
PPBT FAQ – beantwortet von Alphio AI
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Currently, Purple Biotech Ltd is not a strong buy due to its significant financial losses and high volatility. The current price is $1.28, with a 52-week high of $8.90, indicating a potential for recovery but also a risk of further decline. The RSI is at 70.565, suggesting it may be overbought, and the forward P/E ratio is 0, indicating uncertainty in future earnings. The main risk is the projected EPS loss of -2.88 for the upcoming earnings report, which could further impact investor sentiment.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenÄhnliche Artikel
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.